Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cullinan Therapeutics Inc (NQ: CGEM )

18.88 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 39
Open 18.88
Bid (Size) 16.00 (10)
Ask (Size) 20.00 (5)
Prev. Close 18.88
Today's Range 18.88 - 18.88
52wk Range 7.640 - 30.19
Shares Outstanding 199,873,683
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Cullinan Therapeutics Announces Positive Initial Data from Pivotal Phase 2b REZILIENT1 Study of Zipalertinib
Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed... 
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
From Cullinan Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+78.28%
+78.28%
1 Month
-18.52%
-18.52%
3 Month
+23.24%
+23.24%
6 Month
+106.79%
+106.79%
1 Year
+44.45%
+44.45%

More News

Read More
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Oncology: Q4 Earnings Insights
Via Benzinga
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q1 2024
Via InvestorPlace
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Tesla, Deciphera Pharmaceuticals, Heartland Financial And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Is Cullinan Therapeutics Stock Trading Higher On Wednesday?
Via Benzinga
Hilton Worldwide Reports Upbeat Results, Joins Hasbro, Vertiv Holdings And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Why Travelers Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
United Airlines Reports Upbeat Results, Joins Children's Place, Interactive Brokers And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Cullinan Shifts Focus From Oncology To Autoimmune Disorders, Raises $280M Via Equity
Via Benzinga
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Topics Stocks
Exposures US Equities
Cullinan Management Inc. (NASDAQ: CGEM) Records 52-Week High Tuesday Morning
Via Investor Brand Network
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
From Cullinan Therapeutics, Inc.
Via GlobeNewswire
CGEM Stock Earnings: Cullinan Oncology Beats EPS for Q4 2023
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.